|
|
SPOT ON
|
|
Rivaroxaban (XARELTO) now also approved for acute coronary syndrome
|
|
|
NEW ON THE MARKET
|
|
Linaclotide (CONSTELLA) for irritable bowel syndrome with constipation
|
|
|
THERAPY FROM A CRITICAL VIEWPOINT
|
|
Rheumatoid arthritis: biological versus classic DMARDs
|
|
|
a-t READERS' QUESTIONS AND COMMENTS
|
|
Shortened antibiotic treatment due to rebate contract?
URO-VAXOM against recurrent urinary tract infection?
|
|
|
IN BRIEF
|
|
First endpoint study with an incretin-based antidiabetic is negative
Now official: no codeine for children
Bone growth factor dibotermin alfa (INDUCTOS, INFUSE) - paid opinion leaders, ghostwriting, data manipulation and insufficient evidence of benefit
Medical sales representatives without control
Hydroxyl ethyl starch shall be withdrawn from the market
|
|
|
CURRENT ADR NETWORK REPORT
|
|
Renal failure with gyrase inhibitors
|
|
|
SIDE EFFECTS
|
|
The Federal Institute for Drugs and Medical Devices (BfArM) and FUMADERM (dimethyl fumarate and monoethyl fumarates): poor risk management
Finally: restrictions in the use of flupirtine (KATADOLON, generics)
|
|
|
e a-t IN INTERNET
|
|
MUTAFLOR (E. coli Nissle) against sun allergy?
|
|